Immunovant, Inc. (IMVT)
Total Valuation
Immunovant has a market cap or net worth of $2.69 billion. The enterprise value is $2.32 billion.
| Market Cap | 2.69B |
| Enterprise Value | 2.32B |
Important Dates
The last earnings date was Monday, May 22, 2023, before market open.
| Earnings Date | May 22, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 130.41 million shares outstanding. The number of shares has increased by 12.21% in one year.
| Shares Outstanding | 130.41M |
| Shares Change (YoY) | +12.21% |
| Shares Change (QoQ) | +1.35% |
| Owned by Insiders (%) | 58.66% |
| Owned by Institutions (%) | 43.88% |
| Float | 48.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 3,036.42 |
| PB Ratio | 7.43 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.34, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.34 |
| Quick Ratio | 8.71 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -52.40%.
| Return on Equity (ROE) | -52.40% |
| Return on Assets (ROA) | -48.30% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 164 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +403.16% in the last 52 weeks. The beta is 1.02, so Immunovant's price volatility has been similar to the market average.
| Beta (1Y) | 1.02 |
| 52-Week Price Change | +403.16% |
| 50-Day Moving Average | 17.46 |
| 200-Day Moving Average | 13.96 |
| Average Volume (30 Days) | 1,012,528 |
Short Selling Information
The latest short interest is 4.31 million, so 3.30% of the outstanding shares have been sold short.
| Short Interest | 4.31M |
| Short Previous Month | 4.53M |
| Short % of Shares Out | 3.30% |
| Short % of Float | 8.89% |
| Short Ratio (days to cover) | 4.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -218.53M |
| Pretax Income | -210.95M |
| Net Income | -210.96M |
| EBITDA | -209.63M |
| EBIT | -210.95M |
| Earnings Per Share (EPS) | -$1.71 |
Balance Sheet
The company has $376.53 million in cash and $1.22 million in debt, giving a net cash position of $375.31 million or $2.88 per share.
| Cash & Cash Equivalents | 376.53M |
| Total Debt | 1.22M |
| Net Cash | 375.31M |
| Net Cash Per Share | $2.88 |
| Equity / Book Value | 362.49M |
| Book Value Per Share | 2.78 |
| Working Capital | 361.04M |
Cash Flow
In the last 12 months, operating cash flow was -$188.19 million and capital expenditures -$197,000, giving a free cash flow of -$188.39 million.
| Operating Cash Flow | -188.19M |
| Capital Expenditures | -197,000 |
| Free Cash Flow | -188.39M |
| FCF Per Share | -$1.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -7.83% |
| FCF Yield | -6.99% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.21% |
| Shareholder Yield | -12.21% |
Analyst Forecast
The average price target for Immunovant is $23.38, which is 13.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.38 |
| Price Target Difference | 13.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |